Cat.No：GM-87930MAB
Product：Anti-PD1 hIgG1 Reference Antibody (Rosnbio)
Cat.No：GM-87930MAB
Product：Anti-PD1 hIgG1 Reference Antibody (Rosnbio)
GM-87930MAB-1mg / 1 mg
GM-87930MAB-5mg / 5 mg
GM-87930MAB-25mg / 5 mg * 5 vials
GM-87930MAB-50mg / 50 mg
GM-87930MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | PD1 |
Clone | Rosnilimab |
Alternative Names | CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Source/Isotype | Monoclonal Human hIgG1 (KDEL), Kappa |
Application | Bioactivity-ELISA; Assay; Flow cytometry |
Description | Programmed cell death protein-1 (PD-1) is an inhibitory immune checkpoint primarily expressed by immune cells. In the tumor microenvironment, PD-1 binds to its ligands PD-L1 and PD-L2, inhibiting T cell activation and proliferation, which allows tumor cells to evade immune system surveillance. As a novel agonist, Rosnilimab offers a new approach for T cell immune activation and may open new avenues for the treatment of tumors and autoimmune diseases. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
Cat.No：GM-87930MAB
Product：Anti-PD1 hIgG1 Reference Antibody (Rosnbio)
GM-87930MAB-1mg / 1 mg
GM-87930MAB-5mg / 5 mg
GM-87930MAB-25mg / 5 mg * 5 vials
GM-87930MAB-50mg / 50 mg
GM-87930MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | PD1 |
Clone | Rosnilimab |
Alternative Names | CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Source/Isotype | Monoclonal Human hIgG1 (KDEL), Kappa |
Application | Bioactivity-ELISA; Assay; Flow cytometry |
Description | Programmed cell death protein-1 (PD-1) is an inhibitory immune checkpoint primarily expressed by immune cells. In the tumor microenvironment, PD-1 binds to its ligands PD-L1 and PD-L2, inhibiting T cell activation and proliferation, which allows tumor cells to evade immune system surveillance. As a novel agonist, Rosnilimab offers a new approach for T cell immune activation and may open new avenues for the treatment of tumors and autoimmune diseases. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
